PrecisionLife, a leading techbio company driving precision medicine into complex chronic diseases, and Nanopharmaceutics, a clinical-stage pharmaceutical development company, announced today a strategic collaboration aiming to accelerate and de-risk the development of Nanopharmaceutics’ portfolio of central nervous system (CNS) assets.